# This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

> **NCT06451497** · PHASE1 · RECRUITING · sponsor: **Zumutor Biologics Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Pancreas Adenocarcinoma
- Biliary Tract Cancer
- Prostate Cancer
- Urothelial Carcinoma
- Colorectal Cancer
- Triple Negative Breast Cancer
- High Grade Ovarian Serous Adenocarcinoma
- Diffuse Large B Cell Lymphoma
- Renal Cell Cancer Metastatic

## Interventions

- **BIOLOGICAL:** ZM008

## Key facts

- **NCT ID:** NCT06451497
- **Lead sponsor:** Zumutor Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06451497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06451497, "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06451497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*